US grant for Immunomedics' breast cancer agent:
This article was originally published in Clinica
Executive Summary
Immunomedics has received a US grant to test an imaging peptide for diagnosing breast cancer. The company has developed a peptide labelled with the nuclear isotope technetium-99m that binds to a receptor which is increased in breast and several other cancers. The Phase I study is expected to demonstrate the peptide's ability to image human breast cancer.
You may also be interested in...
IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: